EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dasatinib as a Repurposing Candidate for Alzheimer’s Disease: An Integrated In Silico Network Pharmacology and Molecular Docking Study

Nihan Küçük Yılmaz

Trends in Pharmacy · 24.06.2026 · 3 · 1-11

DOI: 10.5152/tip.2026.26015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Pharmacy, online erschienen am 24.06.2026. Verfasst von Nihan Küçük Yılmaz. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer’s disease (AD) lacks broadly effective disease-modifying therapy, and repeated failure of single-target approaches has increased interest in multi-target drug repurposing strategies. Fyn kinase (FYN) is a mechanistic node in the amyloid-β–tau–Fyn pathogenic axis, and dasatinib is an approved multi-kinase inhibitor with potent Src-family activity and preliminary evidence of central nervous system exposure in AD-related studies. The present study aimed to systematically evaluate dasatinib as an AD repurposing candidate through an integrated in silico network pharmacology and molecular docking workflow.

Methods

An integrated in silico workflow was applied using SwissTargetPrediction-based human target prediction, GeneCards disease-gene mining, STRING/Cytoscape protein-protein interaction (PPI) network analysis with degree-centrality hub prioritization, STRING functional enrichment, and CB-Dock2/AutoDock Vina blind molecular docking to the human FYN domain (protein data bank: 2DQ7). Fyn kinase was selected as the docking target based on pre-specified criteria combining AD-specific mechanistic evidence, prior clinical precedent, and top-5 hub ranking.

Results

SwissTargetPrediction identified 100 putative human targets for dasatinib, whereas GeneCards returned 13 890 AD-associated genes; intersection analysis yielded 83 overlapping targets. Degree-centrality analysis ranked epidermal growth factor receptor (EGFR), erb-b2 receptor tyrosine kinase 2 (ERBB2), SRC proto-oncogene non-receptor tyrosine kinase (SRC), ABL proto-oncogene 1 non- receptor tyrosine kinase (ABL1), and Fyn kinase (FYN) as the 5 highest-degree hub nodes. Mitogen-activated protein kinase (MAPK) signaling was the most significantly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, followed by PI3K-Akt signaling and axon guidance, while protein kinase activity was the dominant gene ontology (GO) molecular function term. Blind docking suggested plausible accommodation of dasatinib in the Fyn ATP-binding pocket, with a best AutoDock Vina score of −9.7 kcal/mol and substantial residue-level overlap with the reference compound saracatinib.

Conclusion

Integrated network pharmacology, functional enrichment, and molecular docking support dasatinib as a hypothesis-generating AD repurposing candidate with convergence on Fyn-centered kinase signaling. These findings remain computational and require staged biochemical, pharmacokinetic, cellular, and in vivo validation. Cite this article as: Küçük Yılmaz N. Dasatinib as a repurposing candidate for Alzheimer’s disease: an integrated in silico network pharmacology and molecular docking study. Trends Pharm. 2026, 3, 0015, doi: 10.5152/TIP.2026.26015.

Zitieren

APA

Yılmaz, N. K. (2026). Dasatinib as a Repurposing Candidate for Alzheimer’s Disease: An Integrated In Silico Network Pharmacology and Molecular Docking Study. Trends in Pharmacy, 3, 1-11. https://doi.org/10.5152/tip.2026.26015

Vancouver

Yılmaz NK. Dasatinib as a Repurposing Candidate for Alzheimer’s Disease: An Integrated In Silico Network Pharmacology and Molecular Docking Study. Trends in Pharmacy. 2026;3:1-11. doi:10.5152/tip.2026.26015

BibTeX
@article{Ylmaz2026,
  author = {Yılmaz, Nihan Küçük},
  title = {Dasatinib as a Repurposing Candidate for Alzheimer’s Disease: An Integrated In Silico Network Pharmacology and Molecular Docking Study},
  journal = {Trends in Pharmacy},
  year = {2026},
  volume = {3},
  pages = {1--11},
  doi = {10.5152/tip.2026.26015}
}
Kostenlos starten →